Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
14.69 USD | +0.27% | +15.40% | -56.46% |
Sep. 09 | Pacira Biosciences, Inc. Announces Board Changes | CI |
Aug. 13 | Truist Securities Downgrades Pacira BioSciences to Sell From Buy, Adjusts Price Target to $8 From $30 | MT |
Revenues ($) (Y-1) | Net margin (Y-1) | Operating Margin (Y-1) | ROE (Y-1) | ROA (Y-1) | Leverage (Debt/EBITDA) (Y-1) | ||
---|---|---|---|---|---|---|---|
675M | +6.22% | +29.28% | - | - | 1.14x | ||
34.12B | +15.36% | +20.68% | +48.93% | +9.23% | 2.6x | ||
34.63B | +36.03% | +44.16% | +88.07% | +30.12% | -0.03x | ||
85.16B | +41.28% | +32.25% | +34.91% | +14.32% | 0.21x | ||
54.32B | +8.95% | +45.64% | +143.18% | +14.46% | 1.82x | ||
60.12B | +0.61% | +10.33% | +9.18% | +3.56% | 2.77x | ||
69.43B | +19.58% | +32.77% | +45.73% | +16.71% | 0.85x | ||
45.81B | +13.01% | +31.73% | +29.77% | +11.48% | 1.66x | ||
45.44B | +32.69% | +36.03% | +25.37% | +12.37% | 0.67x | ||
28.19B | +23.83% | +47.53% | +202.85% | +12.37% | 3.07x | ||
58.5B | +3.62% | +15.90% | +11.37% | +4.96% | 3.8x | ||
47.88B | +12.54% | +29.42% | +13.65% | +4.27% | 0.55x | ||
27.12B | +20.89% | +38.66% | +38.46% | +13.49% | 1.34x | ||
45.01B | +17.83% | +37.30% | +51.57% | +8.36% | 1.55x | ||
40.05B | +16.25% | +28.97% | +52.48% | +10.55% | 1.29x | ||
7.83B | +29.29% | +39.52% | +21.30% | +23.34% | -1.57x | ||
11.28B | +12.53% | +13.21% | +12.80% | +7.95% | -2.01x | ||
14.93B | +9.28% | +22.55% | +6.37% | +3.05% | 3.01x | ||
30.04B | +3.38% | +5.02% | +2.10% | +0.36% | 4.66x | ||
Average | 38.97B | +17.01% | +29.52% | +46.56% | +11.16% | 1.44x | |
Weighted average by Cap. | 46.34B | +20.25% | +30.92% | +56.87% | +13.38% | 1.48x |
- Stock Market
- Equities
- PCRX Stock
- Sector Pacira BioSciences, Inc.
- Financial comparisons